pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
480
stories
Jun 8, 26
STAT+: Novo underwhelmed by drug it once fought Pfizer for
stat
Jun 8, 26
#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
endpoints
Jun 8, 26
STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
stat
Jun 8, 26
STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
stat
Jun 7, 26
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
stat
Jun 5, 26
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec
endpoints
Jun 4, 26
Mammalian hair, roof leaks: Novo Nordisk's site in Indiana under FDA scrutiny once again
endpoints
Jun 4, 26
Mammalian hair, roof leaks: Novo Nordisk's site in Indiana under FDA scrutiny once again
endpoints
Jun 4, 26
Novo Holdings backs European fund; Alnylam sends second obesity drug into clinic
endpoints
Jun 4, 26
Alnylam, Inceptive ink AI deal potentially worth $2B
biopharma dive
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
Jun 2, 26
Eli Lilly issues data sharing ultimatum to 340B hospitals
biopharma dive
Jun 1, 26
CDC says containing the spread of Ebola is top priority
stat
Jun 1, 26
STAT+: Medicare still won’t say how much covering obesity drugs will cost
stat
May 28, 26
CVS obesity drug deal puts Lilly on equal footing with Novo
biopharma dive
May 19, 26
Q&A: Novo research chief Petersen says streamlined R&D speeds discovery
endpoints
May 19, 26
STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
stat
May 18, 26
STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
stat
May 13, 26
Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss
biopharma dive
May 13, 26
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
stat
May 12, 26
STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
stat
May 12, 26
A year after Vertex’s big launch, pain drug research faces a pivotal moment
biopharma dive
May 11, 26
Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
endpoints
May 11, 26
New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in China
endpoints
May 11, 26
STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
stat
May 8, 26
STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug
stat
May 8, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
May 8, 26
STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and more
stat
May 7, 26
Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles
stat
May 7, 26
STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
stat
← prev
page 15 of 16
next →
